Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

Obesity has been declared a disease by WHO. It is associated not only with heart disease, diabetes, stroke, gallstones, ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

GUBamy had an 11-day half-life and a pharmacokinetic profile that supports once ... a combination of long-acting amylin ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs ... 36 days in a phase 1 readout in September. Metsera has ...

But the evidence looks only at its effect on overweight or obese people, so we don’t yet know its total impact.Wheate points ...

potential once-monthly injectable GLP-1 RA engineered with Metsera’s HALO™ lipidation platform. MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life.